{"changeSha256":"77fbfec2067302cb25fd81885b2a5e82c5e1fcfc3694d416eb7f4d76895926d6","changedAt":"2026-11-14","changedFields":[{"after":"In clinical trials; not FDA-approved","before":"Investigational","field":"Status"},{"after":"An experimental Amgen antibody-peptide conjugate, also called MariTide, that blocks the GIP receptor and activates the GLP-1 receptor. It is in Phase 3 trials and not FDA-approved.","before":"An antibody-peptide conjugate candidate. This profile cites a completed ClinicalTrials.gov study record.","field":"Profile summary"},{"after":"A large 52-week randomized Phase 2 trial reported weight loss compared with placebo in people with obesity, with common gastrointestinal side effects. Phase 3 trials, including a cardiovascular outcomes trial, are registered.","before":"ClinicalTrials.gov lists an Amgen bioavailability study as completed, updated July 21, 2026.","field":"Evidence note"},{"after":"ctg-nct07717814-v1, journal-pmid-40549887, ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3, ctg-observation-nct07037433-2026-07-24-ae9704758762, ctg-observation-nct07037459-2026-07-02-199638062a19, ctg-observation-nct06660173-2026-09-11-dfcf2dd8720e","before":"ctg-nct07717814-v1","field":"Cited source records"},{"after":"name: ctg-nct07717814-v1; aliases: ctg-nct07717814-v1; category: ctg-nct07717814-v1; status: ctg-nct07717814-v1, ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3, ctg-observation-nct07037433-2026-07-24-ae9704758762; summary: ctg-nct07717814-v1, journal-pmid-40549887, ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3; evidenceNote: journal-pmid-40549887, ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3, ctg-observation-nct07037433-2026-07-24-ae9704758762","before":"name: ctg-nct07717814-v1; aliases: ctg-nct07717814-v1; category: ctg-nct07717814-v1; status: ctg-nct07717814-v1; summary: ctg-nct07717814-v1; evidenceNote: ctg-nct07717814-v1","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/maridebart-cafraglutide/versions/3/","version":3},"id":"profile:maridebart-cafraglutide:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, Phase 2 results from our human evidence review, and retained ClinicalTrials.gov records for Phase 3 trials.","peptideSlugs":["maridebart-cafraglutide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/maridebart-cafraglutide/v2.json","sha256":"6cf4450830982f888b5e0d8b0a258c0629c8c1ea5887d324adfc21b4114686d4"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/maridebart-cafraglutide/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"journal-pmid-40549887","name":"The New England Journal of Medicine","sourceClass":"A","title":"Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial (2025) · PMID 40549887","url":"https://doi.org/10.1056/NEJMoa2504214","verifiedAt":"2026-11-14"},{"id":"ctg-observation-nct06858839-2026-09-17-beb2c75eb0a3","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT06858839 · retained source version 2026-09-17:beb2c75eb0a3bc43ffe1b4c9fab269e89fcf8ae6cbe11f7d4c3ea4213aed3e04","url":"https://clinicaltrials.gov/study/NCT06858839","verifiedAt":"2026-11-14"},{"id":"ctg-observation-nct07037433-2026-07-24-ae9704758762","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT07037433 · retained source version 2026-07-24:ae9704758762002a715a9ed9f57da8845f1a2ea224c8296b8200071653366d78","url":"https://clinicaltrials.gov/study/NCT07037433","verifiedAt":"2026-08-13"}],"subject":{"slug":"maridebart-cafraglutide","type":"profile"}}
